United States Patent [19] [n] Patent Number: 4,742,003
Derynck et al. [45] Date of Patent: May 3, 1988
[54] HUMAN TRANSFORMING GROWTH FACTOR
[75] Inventors: Rik M. A. Derynck, Burlingame;
David V. Goeddel, Hillsborough, both of Calif.
[73] Assignee: Genentech, Inc., South San Francisco, Calif.
[21] Appl. No.: 695,494
[22] Filed: May 14, 1985
Related U.S. Application Data
[63] Continuation-in-part of Ser. No. 581,743, Feb. 17, 1984, abandoned.
[51] Int. CI.* C12P 21/00; C12P 21/02;
C12N 15/00; C12N 1/00
[52] U.S. CI 435/68; 435/70
435/172.3; 435/255; 530/324; 530/350: 530/828; 935/13; 935/28; 935/29; 935/57: 935/47; 935/48
[58] Field of Search 435/68, 172.3, 317,
435/70, 255; 260/112 R, 112 B; 536/27; 935/13, 27, 48, 29, 47, 56, 63, 73, 78; 514/12, 2;
530/324, 350, 828
[56] References Cited
U.S. PATENT DOCUMENTS
4,338,397 7/1982 Gilbert et al 435/68
4,358,586 11/1982 Rubin 536/27
4,511,503 4/1985 Olsen et al 260/112 R
4,546,082 10/1985 Kurjan et al 435/172.3
OTHER PUBLICATIONS
Itakura et al., Science, vol. 198, pp. 1056-1063, 1977, "Expression in Escherichia coli of a Chemically Synthesized Gene for the Hormone Somatostatin". Derynck et al., Cell, vol. 38 (1), pp. 287-297, Aug. 1984, "Human Transformig Growth Factor-Alpha: Precursor Structure and Expression in E. coli". Derynck et al., Nature, vol. 316, pp. 701-705, 1985, "Human Transforming Growth Factor-beta Complementary DNA Sequence and Expression in Normal and Transformed Cells".
Derynck et al., Cancer Cells, vol. 3, (Growth Factors Transform.), pp. 79-86, "Human Transforming Growth Factor-Alpha: Precursor Sequence, Gene Structure and Heterologous Expression".
Tame et al. Proc. Natl. Acad. Sci., vol. 83 (21), pp. 8082-8086, 1986, "Efficient Synthesis of Human Type
Alpha Transforming Growth Factor: Its Physical and Biological Characterization."
Marguardt et al., Proc. Natl. Acad Sci., vol. 80, pp. 4684-4688, Aug. 1983, "Transforming Growth Factors Produced by Retrovirus Transformed Rodent Fibroblust and Human Melanoma Cells: Amino Acid Sequence Homology with Epidermal Growth Factor. Marguardt et al., J. Biol. Chem., vol. 257 (9), May 10, 1982, pp. 5220-5225, "Human Transforming Growth Factor".
Toduro et al., Proc. Natl. Acad. Sci., vol. 77 (9), pp. 5258-5262, Sep. 1980, "Transforming Growth Factors Produced by Certain Human Tumor Cells: Polypeptides that Interact with Epidermal Growth Factor Receptors."
Anzano et al., Proc. Natl. Acad. Sci.,' vol. 80, pp. 6264-6268, Oct. 1983, "Surcoma Growth Factor From Conditioned Medium of Virally Transformed Cells is Composed of both Type a and Type j3 Transforming Growth Factors."
Kemp et al., "P/N.A.S. USA" 78(7): 4520-4524, (Jul. 1981).
Taniguchi et al., "P.N.A.S. USA" 77(9): 5230-5233, (Sep. 1980).
Maniatis, T., "Molecular Cloning, A Laboratory Man- ual" Cold Springs Harbor Lab., Summary 433, (1982). Roberts, T. M., "Promoters, Structure & Function" Rodriguez et al., Ed. 452-461, (1982). Ohsuye, K., et al., "Nucl. Acids Res." 11(5): 1283-1295,
(1983) .
Kadonaga, J., et al., "J. Biol. Chem." 259(4): 2149-2154,
(1984) .
Roberts, A., et al., "P.N.A.S. USA" 77(6): 3494-3498, (Jun. 1980).
Sporn, M., et al., "Molecular Actions and Targets for Cancer Chemotherapeutic Agents" Sartorelli, A., et al., Ed. 542-554, (1981).
Primary Examiner—Thomas G. Wiseman Assistant Examiner—Robin Lyn Teskin
![[blocks in formation]](http://www.google.fr/patents?id=B9swAAAAEBAJ&hl=fr&ie=ISO-8859-1&output=text&pg=PA1&img=1&zoom=3&hl=fr&q=&cds=1&sig=ACfU3U1uNjQhjR5kOtqLnnOky2TN-X9Ccg&edge=0&edge=stretch&ci=490,921,407,153)
ala asp pro pro val ala ala ala VAL VAL GAT CTG AGC CCT GCA TCT TTC CTC TCC CCA GCA GAC CCG CCC GTG GCT GCA GCA GTG GTG
Sau3AI PstI
SER HIS PHE ASN ASP CYS PRO ASP SER HIS THR GLN PHE CYS PHE HIS GLY THR CYS ARG TCC CAT TTT AAT GAC TGC CCA GAT TCC CAC ACT CAG TTC TGC TTC CAT GGA ACC TGC AGG
1 t f
{ Ncol PstI
PHE LEU VAL GLN GLU ASP LYS PRO ALA CYS VAL OC
TTT TTG GTG CAG GAG GAC AAG CCA GCA TGT GTG TAA GTA TCC CCT GTT CTC CTG GAG ATC
Bg^lII
1 10 Met Val Pro Ser Ala Gly Gin Leu Ala Leu Phe Ala Leu Gly lie Val Leu Ala GGGGGGGGGGGGAGGCTGGAGAGCCTGCTGCCCGCCCGCCCGTAAA ATG GTC CCC TCG GCT GGA CAG CTC GCC CTG TTC GCT CTG GGT ATT GTG TTG GCT I 50
20 30 -40
Ala Cys Gin Ala Leu Glu Asn Ser Thr Ser Pro Leu Ser Ala Asp Pro Por Val Ala Ala Ala[Val Val Ser His Phe Asn Asp Cys Pro GCG IGC CAG GCC TTG GAG AAC AGC ACG TCC CCG CTG AGT GCA GAC CCG CCC GTG GCT GCA.GCA GTG GTG TCC CAT TTT AAT GAC TGC CCA 100 [ 150
Pst 1
50 60 70
Asp Ser His Thr Gin Phe Cys Phe His Gly Thr Cys Arg Phe Leu Val Gin Glu Asp Lys Pro Ala Cys Val Cys His Ser Gly Tyr Val GAT TCC CAC ACT CAG TTC TGC TTC CAT GGA ACC TGC AGG TTT TTG GTG CAG GAG GAC AAG CCA GCA TGT GTC TGC CAT TCT GGG TAC GTT
200| | 250
Nco 1 Pst 1
80 90 100
Gly Ala Arq Cys Glu His Ala Asp Leu Leu Ala| Val Val Ala Ala Ser Gin Lys Lys Gin Ala lie Thr Ala Leu Val Val Val Ser He GGT GCA CGC TGT GAG CAT GCG GAC CTC CTG GCC GTG GTG GCT GCC AGC CAG AAG AAG CAG GCC ATC ACC GCC TTG GTG GTG GTC TTC ATC
300 350 110 120 130
Val Ala Leu Ala Val Leu lie He Thr Cys Val Leu He His Cys Cys Gin Val Arg Lys His Cys Glu Trp Cys arg Ala Leu He Cys GTG GCC CTG GCT GTC CTT ATC ATC ACA TGT GTG CTG ATA CAC TGC TGC CAG GTC CGA AAA CAC TGT GAG TGG TGC CGG GCC CTC ATC TGC
400
140 150 160 *
Arg His Glu Lys Pro Ser Ala Leu Leu Lys Gly Arg Thr Ala Cys Cys His Ser Glu Thr Val Val OP
CGG CAC GAG AAG CCC AGC GCC CTC CTG AAG GGA AGA ACC GCT TGC TGC CAC TCA GAA ACA GTG GTC TGA AGAGCCCAGAGGAGGAGTTTGGCCAGG 450 500
TGGACTGTGGCAGATCAATAAAGAAAGGCTTCTTCAGGACAGCACTGCCAGAGATGCCTGGGTGTGCCACAGACCTTCCTACTTGGCCTGTMTCACCTGTGCAGCCTTTTGTGGGCCT 550 600 650
TCAAAACTCTGTCAAGMCTCCGTCGGCTTGGGGTTATTC.GTGTGACCTAGAGAAGAAATCAGCGGACCACGATTTCMGACTTGTTAAAAAAGAACTGCAAAGAGACGGACTCCTGT
700 Nco 1 7 50
TCACCTAGGTGAGGTGTGTGCAGCAGTTGGTGTCTGAGTCLACATGTGTGCAGTTGTCTTCTGCCAGCCATGGATTCCAGGCCSTCCCCCCCCCCCCCCCCCCC FiQ J 800 850
« PrécédentContinuer » |